Can Effective Delivery of Curcumin be Used to Suppress Cancer Cell Growth?

Augustus BioTarget, Inc.
Little River, South Carolina
DOI: 10.18258/9800
Raised of $4,500 Goal
Funded on 10/07/17
Successfully Funded
  • $7,035
  • 156%
  • Funded
    on 10/07/17



This video is a cartoon of the CLR-Targosphere which we have contracted from Rodos Biotarget GmbH in Germany.

It encapsulates Curcumin which is then delivered exclusively to the immune system's Antigen Presenting Cells (APCs). The APCs containing Curcumin travel to tumor sites and deliver the encapsulated Curcumin directly to tumor cells as well as Cytotoxic T-Lymphocytes to help restore a therapeutic Death Receptor response to tumor-specific antigens.

We have shown that the CLR-TargoSphere also crosses the Blood Brain Barrier, enabling the potential for treatment of neurodegenerative and neuroinflammatory diseases with curcumin in combination with other drugs.

We here at Augustus BioTarget are employing the nanocarrier for oncologic indications as well as the treatment of neurodegenerative diseases including Alzheimer's, Parkinson's Disease, Multiple Sclerosis, and Chronic Traumatic Encephalopathy such as is seen in athletes who suffer multiple repeated minor head injuries.


This project has not yet shared any protocols.